<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173403</url>
  </required_header>
  <id_info>
    <org_study_id>AK102-204</org_study_id>
    <nct_id>NCT04173403</nct_id>
  </id_info>
  <brief_title>A Long-term Study of AK102 in Patients With Hypercholesterolemia</brief_title>
  <official_title>A Long-term Study to Evaluate the Efficacy and Safety of AK102 in Combination With Lipid-lowering Therapy in Patients With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AD Pharma (Guangdong)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, open-label, non-controlled, extended study. The main objective of this
      study is to evaluate the long-term efficacy and safety of AK102 in combination with basic
      lipid-lowering therapy in patients with hypercholesterolemia. Subjects who have participated
      in the AK102 studies and have completed the last visit,and who, in the opinion of the
      investigator, are likely to benefit from continued treatment will be enrolled in this study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 52</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events as assessed by CTCAE V5.0</measure>
    <time_frame>From baseline through 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-density lipoprotein (HDL) cholesterol</measure>
    <time_frame>From baseline through 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in non High-density lipoprotein (non-HDL) cholesterol</measure>
    <time_frame>From baseline through 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Triglyceride (TG) cholesterol</measure>
    <time_frame>From baseline through 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B (Apo B)</measure>
    <time_frame>From baseline through 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein A-I (Apo A-I)</measure>
    <time_frame>From baseline through 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From BaPercent Change From Baseline in Total Cholesterol(TC)</measure>
    <time_frame>From baseline through 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)</measure>
    <time_frame>From baseline through 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of AK102 in Serum</measure>
    <time_frame>From baseline through 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>From baseline through 52 weeks</time_frame>
    <description>The immunogenicity of AK102 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>AK102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>450mg AK102, Q4W, subcutaneous injection; OR 300mg AK102, Q4W, subcutaneous injection;OR 150mg AK102, Q4W, subcutaneous injection;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>450mg AK102</intervention_name>
    <description>AK102 Q4W</description>
    <arm_group_label>AK102</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300mg AK102</intervention_name>
    <description>AK102 Q4W</description>
    <arm_group_label>AK102</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150mg AK102</intervention_name>
    <description>AK102 Q2W</description>
    <arm_group_label>AK102</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statins and/or Ezetimibe</intervention_name>
    <description>Lipid-lowering therapies</description>
    <arm_group_label>AK102</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent.

          2. Body weight â‰¥ 40 kg for both men and women.

          3. Participated in the AK102-202 study, and completed the AK102-202 study last visit.

        Exclusion Criteria:

          1. Poor compliance in AK102-202 study per investigator's judgement.

          2. AE that led to permanent discontinuation of AK102 occurred during the AK102-202 study
             period.

          3. Prior use of PCSK9 inhibitors other than AK102.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuyang Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Liu</last_name>
    <phone>0760-89873998</phone>
    <email>clinicaltrials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Peipei Chen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shuyang Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 17, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

